CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma

被引：0
|
作者：
Zeyana, Rivera [1 ]
Ferrone, Soldano [2 ,3 ,4 ]
Wang, Xinhui [2 ,3 ,4 ]
Sandro, Jube [1 ]
Yang, Haining [1 ]
Gaudino, Giovanni [1 ]
Carbone, Michele [1 ]
机构：
[1] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA
[2] Univ Pittsburgh, Dept Surg, Inst Canc, Pittsburgh, PA USA
[3] Univ Pittsburgh, Dept Immunol, Inst Canc, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Pathol, Inst Canc, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-2514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2514
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
    W Leconet
    C Larbouret
    T Chardès
    G Thomas
    M Neiveyans
    M Busson
    M Jarlier
    N Radosevic-Robin
    M Pugnière
    F Bernex
    F Penault-Llorca
    J-M Pasquet
    A Pèlegrin
    B Robert
    Oncogene, 2014, 33 : 5405 - 5414
  • [32] Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy
    Roy, Allison G.
    Robinson, J. Michael
    Sharma, Prannda
    Rodriguez-Garcia, Alba
    Poussin, Mathilde A.
    Nickerson-Nutter, Cheryl
    Powell, Daniel J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [33] CSPG4 as innovative target for CAR redirected CIK lymphocytes against soft tissue sarcomas
    Leuci, Valeria
    Rotolo, Ramona
    Donini, Chiara
    Mesiano, Giulia
    Fiorino, Erika
    Gammaitoni, Loretta
    Grignani, Giovanni
    D'Ambrosio, Lorenzo
    Ferrone, Soldano
    Dotti, Gianpietro
    Aglietta, Massimo
    Sangiolo, Dario
    CANCER RESEARCH, 2018, 78 (13)
  • [34] Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease
    Larabee, Jason L.
    Doyle, D. Annie
    Ahmed, Ummey Khalecha Bintha
    Shadid, Tyler M.
    Sharp, Rachel R.
    Jones, Kenneth L.
    Kim, Young Mi
    Li, Shibo
    Ballard, Jimmy D.
    PLOS PATHOGENS, 2023, 19 (03)
  • [35] B7-H3 targeted antibody-based immunotherapy of malignant diseases
    Michelakos, Theodoros
    Kontos, Filippos
    Barakat, Omar
    Maggs, Luke
    Schwab, Joseph H.
    Ferrone, Cristina R.
    Ferrone, Soldano
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (05) : 587 - 602
  • [36] Antibody-based technologies for target discovery
    Valle, RPC
    Jendoubi, M
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2003, 6 (02) : 197 - 203
  • [37] CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate
    Mungra, Neelakshi
    Biteghe, Fleury A. N.
    Malindi, Zaria
    Huysamen, Allan M. M.
    Karaan, Maryam
    Hardcastle, Natasha S. S.
    Bunjun, Rubina
    Chetty, Shivan
    Naran, Krupa
    Lang, Dirk
    Richter, Wolfgang
    Hunter, Roger
    Barth, Stefan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) : 12203 - 12225
  • [38] Current perspectives of bispecific antibody-based immunotherapy
    Talac, R
    Nelson, H
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2000, 14 (03): : 175 - 181
  • [39] Monoclonal antibody-based immunotherapy for multiple myeloma
    Danylesko, Ivetta
    Beider, Katia
    Shimoni, Avichai
    Nagler, Arnon
    IMMUNOTHERAPY, 2012, 4 (09) : 919 - 938
  • [40] European approach to antibody-based immunotherapy of melanoma
    Altomonte, M
    Maio, M
    SEMINARS IN ONCOLOGY, 2002, 29 (05) : 471 - 478
12345